NBW Capital LLC Buys 4,152 Shares of Repligen Co. (NASDAQ:RGEN)

NBW Capital LLC grew its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 19.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,194 shares of the biotechnology company's stock after buying an additional 4,152 shares during the period. NBW Capital LLC's holdings in Repligen were worth $3,626,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in RGEN. UMB Bank n.a. lifted its stake in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares during the period. First Turn Management LLC bought a new stake in shares of Repligen during the 3rd quarter worth $13,202,000. Thrivent Financial for Lutherans boosted its position in shares of Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock valued at $95,037,000 after purchasing an additional 36,773 shares during the period. Geneva Capital Management LLC increased its stake in Repligen by 8.5% in the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company's stock worth $20,638,000 after purchasing an additional 10,908 shares in the last quarter. Finally, TimesSquare Capital Management LLC raised its holdings in Repligen by 14.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company's stock worth $41,019,000 after buying an additional 35,115 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Remove Ads

Repligen Stock Down 2.8 %

Shares of Repligen stock traded down $4.41 during trading on Friday, hitting $155.70. 923,847 shares of the stock traded hands, compared to its average volume of 618,521. The stock has a market cap of $8.72 billion, a P/E ratio of -305.29, a PEG ratio of 4.54 and a beta of 0.99. The company has a fifty day moving average price of $157.02 and a two-hundred day moving average price of $148.62. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $203.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Equities research analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on RGEN shares. StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a report on Friday, February 21st. Canaccord Genuity Group increased their target price on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a report on Friday, February 21st. Royal Bank of Canada upped their price target on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research report on Friday, February 21st. JPMorgan Chase & Co. increased their price objective on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Finally, Wolfe Research started coverage on Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating on the stock. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, Repligen currently has an average rating of "Moderate Buy" and an average price target of $181.00.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.